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Meizothrombin Formation during  Factor Xa-catalyzed 
Prothrombin  Activation 
FORMATION IN A PURIFIED SYSTEM AND IN PLASMA* 
(Received for publication, January 14, 1991) 
Guido Tans$,  Truus  Janssen-Claessen, H. Coenraad  Hemker,  Robert F. A. Zwaal, and  Jan Rosing 
From the Department of Biochemistry, Cardwuasculur Research Institute, University of Limburg, 
6200 MD Maastricht, The Netherlands 
Meizothrombin and  thrombin  formation  were  quan- 
titated  during  factor  Xa-catalyzed  activation of human 
prothrombin  in  reaction  systems  containing  purified 
proteins  and  in plasma. In  the  purified system  consid- 
erable  amounts of meizothrombin  accumulated  when 
prothrombin  was  activated by factor Xa (with  or  with- 
out accessory components) under  initial  steady state 
conditions. The  ratio of the  rates of meizothrombin and 
thrombin  formation  was  not  influenced  by  variation of 
the pH, temperature,  or ionic strength of the reaction 
medium. When 2 PM prothrombin  was  activated  by  the 
complete prothrombinase complex (factor Xa, factor 
Va, Ca2+, and phospholipid) SO-90% of the initially 
formed  reaction  product  was  meizothrombin.  Lower- 
ing  the  prothrombin  concentration  from 2 to 0.03 PM 
caused  a gradual  decrease in  the  ratio of meizothrom- 
binlthrombin  formation  from 5 to 0.6. When the phos- 
phatidylserine  content of the phospholipid  vesicles was 
varied between 20 and 1 mol % and prothrombin  acti- 
vation  was  analyzed at 2 I.~M prothrombin  the  relative 
amount of meizothrombin  formed  decreased from 85 
to 55%. With platelets,  cephalin, or thromboplastin as 
procoagulant  lipid,  thrombin  was  the  major  reaction 
product and only 30-40% of the activation product 
was meizothrombin. We also  analyzed  complete  time 
courses of prothrombin  activation  both  with  purified 
proteins  and  in plasma. In  reaction  systems  with  puri- 
fied proteins substantial amounts of meizothrombin 
accumulated under a  wide  variety of experimental con- 
ditions.  However, little  or no  meizothrombin was de- 
tected in plasma in  which  coagulation  was  initiated  via 
the  extrinsic  pathway  with  thromboplastin  or  via  the 
intrinsic  pathway  with  kaolin plus  phospholipid (ce- 
phalin,  platelets, or phosphatidylserine-containing 
vesicles). Thus, thrombin was the only active pro- 
thrombin  activation  product that accumulated during 
ex vivo coagulation experiments  in plasma. 
The conversion of prothrombin  into  a-thrombin by coagu- 
lation factor Xa is one of the central reactions of blood 
coagulation (for recent reviews, see Refs. 1, 2). Thrombin 
formation is the result of cleavage of the Arg273-Thr274 and 
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Arg322-Ile323 bonds in  the prothrombin molecule, and depend- 
ing upon the order of peptide bond cleavage  two intermediary 
products  (prethrombin 2 and meizothrombin)’ may accumu- 
late  during  prothrombin activation. It is now  well established 
that both prethrombin 2 (3-5) and meizothrombin (2, 5-8) 
can indeed be formed during factor Xa-catalyzed prothrombin 
activation, which means that two enzymatically active reac- 
tion products, i.e. thrombin and meizothrombin may accu- 
mulate when prothrombin is activated by factor Xa. Kinetic 
studies of prothrombin activation in reaction systems with 
purified bovine proteins  under steady state  (initial  rate) con- 
ditions have shown that meizothrombin is actually the major 
reaction product which accounts for 70-80%  of the amidolytic 
activity generated (6, 7). Although both  thrombin  and mei- 
zothrombin have nearly identical activity toward the chro- 
mogenic substrate S2238, they exhibit different activities 
toward physiological thrombin  substrates. Meizothrombin has 
been reported to have less than 5% of the activity of thrombin 
toward fibrinogen (6, 9-12), factor V (12), and platelets (12). 
Thombin and meizothrombin are equally well inhibited by 
the plasma protease inhibitor AT 111’ (13). Heparin does not 
promote the inhibition of meizothrombin by AT I11 whereas 
it greatly accelerates the inactivation of thrombin by this 
inhibitor  (13). It has been reported (12), however, that mei- 
zothrombin is able to activate  protein C with about 75% of 
the activity of thrombin. Based on the observation that mei- 
zothrombin lacks the procoagulant properties of a-thrombin 
whereas it exhibits considerable activity in protein C activa- 
tion, it has been postulated that meizothrombin may have an 
anticoagulant function and  that  the generation of a-thrombin 
may predominantly serve procoagulant functions (12). 
In view  of a possible role of meizothrombin in  the regulation 
of hemostatic plug formation, it is of interest to know whether 
different experimental conditions influence the relative rates 
at which thrombin  and meizothrombin are produced during 
prothrombin activation. In the present study we investigated 
in  a model system with purified human  proteins the effect of 
The nomenclature used for proteolytically derived products of 
prothrombin is that recommended by the International Committee 
on Thrombosis and Haemostasis (Jackson, C. M. (1977) Thromb. 
Haemostasis 38,567-577). 
* The abbreviations used are: A T  111, antithrombin 111; Hepes, 4- 
(2-hydroxyethyl)-l-piperazineethanesulfonic acid; SDS, sodium do- 
decyl sulfate; a,”, a,-macroglobulin; BSA, bovine serum albumin; 
DOPC, 1,2-dioleoyl-sn-glycerophosphocholine; DOPS, 1,2-dioleoyl- 
sn-glycerophosphoserine; DOPE, 1,2-dioleoyl-sn-glycerophosphoe- 
thanolamine; egg-PC, egg  yolk phosphatidylcholine; brain-PS, bovine 
brain phosphatidylserine; 12581, N-dansyl-(p-guanidine)-phenylala- 
nine-piperidide hydrochloride; S2238, D-phenylalanyl-L-pipecolyl-L- 
arginine-p-nitroanilide; PPACK, phenylalanyl-prolyl-arginine chlo- 
romethyl ketone; p-NPGB, p-nitrophenyl-p’-guanidinobenzoate hy- 
drochloride; RVV-X, purified activator from  Russell’s viper venom. 
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Meizothrombin  Formation in a Purified System and in Plasma 21865 
different reaction conditions ( i e .  prothrombinase composi- 
tion, protein concentrations, phospholipid composition and 
concentration,  and  pH,  temperature,  and ionic strength of the 
reaction medium) on meizothrombin and  a-thrombin  forma- 
tion.  Furthermore, we have analyzed prothrombin  activation 
in plasma in an  attempt  to establish whether meizothrombin 
accumulates during coagulation of plasma. 
EXPERIMENTAL  PROCEDURES 
Materials 
Ovalbumin (grade V), benzamidine-HC1, Russell's viper venom, 
Echis  carinatus venom, soybean trypsin  inhibitor  (Type IS), rabbit 
brain cephalin, egg  yolk PC, DOPC, DOPE, bovine brain PS,  and  the 
calcium-ionophore A23187  were purchased from Sigma. Kaolin (light) 
was from BDH. Cholesterol (99% pure) was obtained from Merck. 
Horse  tendon collagen (Type I) was from Hormon Chemie, Munich, 
Germany and 12581,  S2337, and S2238 were obtained from AB Kabi 
Diagnostica, Sweden. PPACK was purchased from Calbiochem, La 
Jolla, CA. p-NPGB was obtained from Nutritional Biochemicals. 
Reptilase reagent was from Boehringer, Mannheim, Germany. Aga- 
rose (Indubiose A37-HAA) was from IBF Biotechnics, France. Crude 
porcine intestinal mucosal heparin (175 USP/mg) was from Organon, 
The Netherlands. Swine anti-rabbit IgG horseradish peroxidase-con- 
jugated antibodies were obtained from Nordic, Tilburg, The Nether- 
lands. 3.3'-Diaminobenzidinetetrahydrochloride was from Fluka AG, 
Switzerland. All other reagents were of the highest grade commer- 
cially available. 
Methods 
Proteins-The proteins used in this study were purified from fresh 
frozen human plasma. Prothrombin and factor  X were purified ac- 
cording the method of diScipio et al. (14). A T  I11 was isolated as 
described by Thaler  and Schmer (15). Factor  Xa was obtained from 
purified factor X  after activation with RVV-X and isolation of the 
factor Xa from the activation mixture by affinity chromatography on 
soybean trypsin  inhibitor-Sepharose as described by  Bock et al. (16). 
RVV-X was purified from the crude venom of Russell's viper accord- 
ing  the method of Schiffmann et al. (17). a-Thrombin was prepared 
by activation of prothrombin (20 mg) at  37 "C in 10 ml of buffer 
containing 50 mM Tris, pH 7.9, 100 mM NaCl, 2 mM CaC12, 50 p M  
phospholipid vesicles (brain-PS/egg-PC, 20/80; mol/mol), 2.5  nM 
factor Xa, 4 nM factor Va, and 20 p~ 1-2581. The reversible thrombin 
inhibitor I2581  was present to prevent  autocatalytic degradation of 
a-thrombin. Prothrombin activation was complete within 10 min 
after which the cy-thrombin  was purified from the reaction mixture 
as described by Pletcher and Nelsestuen (18). Meizothrombin, mei- 
zothrombin-des-fragment 1, and thrombin used to set  up the assays 
were freshly prepared before each experiment as follows. Meizothrom- 
bin was obtained by activation of 1 p~ prothrombin with E.  carinatus 
venom in the presence of the reversible thrombin inhibitor 12581. 
Prothrombin was activated at 37 "C  in  a total volume of 200 p1 of 
buffer containing 50 mM Tris,  pH 7.9,  175 mM NaCl, 5 mM CaCI?, 20 
p M  12581, and 20 pg/ml E. carinatus venom. Under these conditions 
all prothrombin was converted into meizothrombin within 1 min. 
Due to the presence of the thrombin inhibitor 12581, there was 
negligible formation of meizothrombin-des-fragment 1. The reaction 
was stopped after 1 min by diluting the reaction mixture 10-fold with 
ice-cold buffer. Meizothrombin-des-fragment 1 was prepared by ac- 
tivating  4 p M  prothrombin at 37 "C in 200 p1 of buffer containing 50 
mM Tris, pH 7.9, 175 mM NaCl, 5 mM CaC12, and 40 pg/ml E. 
carinatus venom. After 2 min all prothrombin  had been converted to 
meizothrombin-des-fragment 1 and  the reaction was stopped by di- 
luting the reaction mixture 40-fold into ice-cold buffer. Thrombin 
was obtained from the same reaction mixture by allowing autocata- 
lysis to proceed for 1 h at 37 "C during which all meizothrombin-des- 
fragment 1 was quantitatively converted to thrombin  (i.e.  thrombin 
lacking residues 1-13  of the A-chain). The meizothrombin and mei- 
zothrombin-des-fragment 1 thus prepared were used within 1 h during 
which time period no further autocatalysis occurred. When meizo- 
thrombin and meizothrombin-des-fragment 1 were prepared for gel 
electrophoretic experiments the reaction samples were quenched with 
gel sample buffer. 
Factor V was purified essentially as described by Dahlback and 
colleagues (19, 20) with minor modifications. To fresh frozen plasma 
the irreversible thrombin inhibitor PPACK was added to a final 
concentration of 2 pM. All buffer solutions used in the isolation 
procedure contained 250 nM PPACK. The final purification step 
(chromatography on AcA22) was performed with a buffer solution 
that did not  contain  PPACK. The presence of PPACK was necessary 
to obtain reproducible preparations of homogeneous and single chain 
factor V (>95%). Factor Va was prepared by activation of factor V 
(0.3 mg/ml) at 37 "C for 30 min with 30 nM thrombin  in 50 mM Tris, 
pH 7.9,175 mM NaC1, 20% (v/v) glycerol, and 5 mM CaC12. After the 
activation was complete, 30 nM PPACK was added to inhibit the 
thrombin present in the activation mixture. The small amount of 
remaining PPACK did not  interfere with the reactions carried out 
with the factor Va preparations. Factor Va was subsequently diluted 
1/10  in 10 mM Hepes, pH 7.5 at room temperature, 136 mM NaCI, 5 
mM CaC12,  2.68 mM KC1, 2 mM MgC12,  25 mM glucose, and 5 mg/ml 
BSA and stored at -80 "C. Factor Va  was stable for several months 
at -80 "C and lost about  10% of its activity when kept on ice for 6 h. 
Protein  preparations were homogeneous and >95% pure as judged 
by polyacrylamide gel electrophoresis in the presence of SDS accord- 
ing to Laemmli (21). Protein concentrations were routinely deter- 
mined according to Lowry et al. (22) using BSA as a  standard. Molar 
concentrations of thrombin (23) and factor Xa (24) were determined 
by active site titration with p-NPGB. Molar concentrations of mei- 
zothrombin and meizothrombin-des-fragment 1 were determined with 
the chromogenic substrate S2238 using a calibration curve made with 
known amounts of thrombin as a  standard.  Prothrombin  concentra- 
tions were determined  after complete activation of prothrombin with 
E. carinatus venom after which the amidolytic activity obtained was 
used to calculate the original amount of prothrombin present. Con- 
centrations of factor Va  were determined kinetically as described for 
bovine factor Va  by Lindhout et al. (25). 
Lipid Preparations-DOPS was prepared from DOPC by enzy- 
matic synthesis according to Comfurius and Zwaal(26). Phospholipid 
vesicles  were prepared as described earlier (4). Human brain  throm- 
boplastin was purified according to a modification of the method of 
Owren and Aas (27) as described by van Dam-Mieras et al. (28) and 
was stored at -80  "C in Tris-buffered saline (10 mM Tris,  pH 7.4,  150 
mM NaC1). Rabbit  brain cephalin was reconstituted in Tris-buffered 
saline according to  the manufacturer's instructions. 
Defibrinated Plasma Preparations-Normal human plasma, ob- 
tained as described in van Dam-Mieras et al. (28), was defibrinated 
prior to use by incubation of 1 ml of plasma with 25 pl of reptilase 
reagent for 20 min at 37 "C. The plasma was placed on ice for 10 min, 
and  the precipitated fibrin was subsequently removed by centrifuga- 
tion. The defibrinated plasma thus obtained contains normal levels 
of coagulation factors  (29). Defibrinated plasma was used to facilitate 
sampling from plasma-containing reaction mixtures in which other- 
wise clotting would have occurred. As judged by control experiments 
with purified proteins, the presence of reptilase did neither  interfere 
with the assays of prothrombin activation products nor with the time 
courses of prothrombin activation. 
Platelet Preparations-Washed human platelets were obtained 
from healthy  consenting donors by venipuncture and isolation of the 
platelets as described before (30).  In the final step of the isolation 
procedure, the platelets were resuspended at a final concentration of 
1 X 109/ml in 10 mM Hepes, pH 7.5 at 37 "C, 136 mM NaC1,  2.68 mM 
KC1, 2 mM MgCl,, 25 mM glucose, and 0.5%  BSA. Platelet concen- 
trations were determined with a Coulter counter. 
Gel Electrophoretic Procedures-Gel electrophoresis of prothrom- 
bin activation products was carried out on 10% polyacrylamide slab 
gels (5%  stacking gel) in the presence of SDS according to Laemmli 
(21) in a Protean I1 cel from Bio-Rad. Electrophoretic transfer to 
nitrocellulose sheets was carried out as described by Towbin et al. 
(31).  Transfer was routinely performed overnight at 10 "C with 125- 
mA current in  a Protean I1 blot module from Bio-Rad. Visualization 
of amidolytically active prothrombin activation products as well as 
immunologic detection of prothrombin  and  its activation products on 
the nitrocellulose sheets were performed as described earlier (8). 
Quantitative Analysis of Prothrombin Activation-Rates of pro- 
thrombin activation in the purified system were determined under 
initial  rate conditions as described earlier (4). Quantitation of throm- 
bin and meizothrombin3 was performed as described before (6) by 
Our amidolytic assays do not discriminate between meizothrom- 
bin and meizothrombin-des-fragment 1 since the activities of both 
enzymes toward S2238 are the same and they exhibit the same 
kinetics of inhibition by A T  I11 plus heparin. In those cases where 
meizothrombin formation is quantitated it actually represents the 
sum of meizothrombin and meizothrombin-des-fragment 1 present in 
the reaction mixture. 
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21866 Meizothrombin  Formation in a Purified  System and in Plasma 
determination of the  total amidolytic activity toward S2238 which 
measures both enzymatically active prothrombin activation products, 
thrombin and meizothrombin (assay l), and by determination of the 
activity remaining after 1 min of incubation with 5 nM AT 111 in the 
presence of 20 pg/ml heparin which only measures meizothrombin 
(assay 2). From the amounts of activated  prothrombin  (assay 1) and 
of meizothrombin present (assay 2), the initial  rates of prothrombin 
activation and meizothrombin formation were calculated. The  rate of 
thrombin formation was subsequently calculated from the difference 
between the overall rate of prothrombin activation and  the rate of 
meizothrombin formation. 
When prothrombin activation is monitored in plasma, az-M-inhib- 
ited prothrombin activation products contribute to the amidolytic 
activity (29, 32), measured in both assays, and  this precludes direct 
quantitation of thrombin and meizothrombin. Thus,  an additional 
third amidolytic assay was performed in order to  quantitate nz-M- 
inhibited prothrombin activation products. In this latter assay an 
aliquot from the reaction mixture was transferred to a cuvette con- 
taining 25 nM AT I11 and 20 pg/ml heparin. Under these conditions 
thrombin  and meizothrombin were completely inhibited, whereas the 
activity of a2-M-inhibited  thrombin species remained unaffected (see 
also “Results”). 
RESULTS4 
In this paper we have used two different approaches to 
analyze the kinetics of time courses of prothrombin  activation. 
In  the model system (first part of this  paper), we have deter- 
mined the effect of the reaction conditions on initial  rates of 
meizothrombin and thrombin formation. The experimental 
conditions were chosen such that prothrombin was always 
present in excess and  that rates of meizothrombin and  throm- 
bin formation were constant  in  time indicating that such low 
amounts of reaction intermediates (e.g. meizothrombin) were 
formed that  their  rate of production greatly exceeded the rate 
by which they were converted into  thrombin.  In  our experi- 
mental setup, prothrombin activation was started by the 
addition of prothrombin to reaction mixtures in which factor 
Xa was preincubated for 5 min at 37 “C with accessory com- 
ponents (factor Va, Ca2+,  and/or phospholipid). Under these 
conditions there was no delay in  the onset of prothrombin 
activation. Rates of meizothrombin and  thrombin formation 
were calculated from the  amounts of product generated in the 
initial  phase of the reaction (activation times t5 min) over a 
time interval in which less than 4% of the prothrombin 
present was converted into enzymatically active products 
(thrombin, meizothrombin). In the plasma system (second 
part of this  paper), we have analyzed complete time courses 
of activation thus allowing further conversion of accumulated 
reaction intermediates. 
It should be emphasized that we have only quantitated  the 
generation of enzymatically active prothrombin activation 
products  (thrombin and  mei~othrornbin~)  and  that we did not 
consider the formation of prethrombin 2. This intermediate 
is only formed at appreciable amounts when prothrombin is 
activated by factor Xa in the absence of factor Va (4, 5,  33). 
The Effect of the  Composition of the  Prothrombin-activating 
Complex on  Initial Rates of Meizothrombin and Thrombin 
Formation-Table I shows the effect of variation of the com- 
position of the prothrombin-activating complex on the overall 
rate of prothrombin activation and  on  the relative amounts 
of thrombin  and meizothrombin that  are formed in  the initial 
phase of the reaction. This experiment was carried out at 2 
~ L M  prothrombin, which approximates the plasma prothrom- 
bin concentration. In agreement with the literature (cf. Refs. 
Portions of this paper (Figs. 1, 2A,  3A, 7, and 8) are  presented in 
miniprint at  the end of this paper. Miniprint is easily read with the 
aid of a  standard magnifying glass. Full size photocopies are included 
in  the microfilm edition of the  Journal  that is available from Waverly 
Press. 
TABLE I 
Initial rates of thrombin and rneizothrombin formation in the absence 
and presence of accessory components 
Initial  rates of prothrombin activation were determined as follows. 
Factor  Xa was preincubated at 37 “C in 335 p1 of buffer containing 
10 mM Hepes, pH 7.5 at 37 “C, 136 mM NaC1, 2.68 mM KCl, 2 mM 
MgCIz, 25 mM glucose, 5 mg/ml  BSA in the absence or presence of 
CaCL, factor Va, and phospholipid vesicles (DOPS/DOPC, 80/20; 
mol/mol). After 5 min, the reaction was started with the addition of 
15 ~1 of prothrombin  in the same buffer. The final  concentrations 
reached in the reaction mixture were 10 mM Hepes, pH 7.5 at 37 “C, 
136 mM NaC1, 2.68 mM KC1, 2 mM MgC12, 25 mM glucose, 5 mg/ml 
BSA, 2 p~ prothrombin, and amounts of  CaC12, factor Xa, factor Va, 
and phospholipid vesicles (PL)  as indicated in the table. In the case 
where CaClz was absent the reaction was carried out in the presence 
of 5 mM EDTA. The initial  rates of thrombin and meizothrombin 
(plus meizothrombin-des-fragment 1) formation were determined as 
described earlier (4, 6). For further experimental details see also 
under  “Experimental Procedures.” 
u (mol/min/mol Xa) 
Activator % Thrombin Meizothrombin meizo 
formation formation 
Xa (25 nM) 0.0011 0.0034 76 
Xa (40 nM),  CaCL (2 mM) 0.0046 0.0110 71 
Xa (4 nM), CaClz (2 mM), PL 0.0718 0.4235 86 
Xa (4 nM), CaClz (2 mM),  Va 5.69 1.46 20 
Xa (4 PM), CaClz (2 mM),  Va 619 5016 89 
(100 FM) 
(60 nM) 
(4 nM), PL (100 p M )  
1, 2) the accessory components, factor Va and phospholipid, 
greatly stimulated the overall rate of prothrombin activation. 
Analysis of the amidolytically active products generated in- 
dicated that with all compositions of the prothrombinase 
complex substantial  amounts of meizothrombin were  formed. 
With  a  prothrombin-activating complex consisting of factor 
Xa, factor Va, and CaC12, the  rate of meizothrombin accu- 
mulation was some 4-fold lower than  the rate of thrombin 
formation. In all  other cases meizothrombin was formed in 
excess of thrombin and accounted for about 80% of the 
enzymatically active product generated under initial steady 
state rate conditions. These results are in agreement with 
data  that we obtained earlier with bovine coagulation factors 
(2, 6). 
The experiment presented in Table I was performed at 
optimal  concentrations of accessory components. The relative 
amounts of meizothrombin and  thrombin formed with each 
composition of prothrombinase complex were, however, not 
influenced by variation of the amounts of factor Xa or factor 
Va present nor were they affected by changing the concentra- 
tions of CaClz (0.5-10 mM) or phospholipid (5-200 p M  in  the 
absence of factor Va and 0.5-200 p~ in the presence of factor 
Va; data  not shown). The phospholipid concentration ranges 
were chosen such that  the contribution of the reaction in free 
solution remained negligible, and product generation was the 
result of lipid-dependent prothrombin activation. 
The Effect of Variation of pH, Temperature, and Ionic 
Strength  on  Thrombin  and  Meizothronbin  Formation  during 
Prothrombin Actiuation-Fig. 1 (Miniprint) shows the effect 
of variation of the  pH, ionic strength,  and  temperature on the 
overall rate of prothrombin activation, i.e. meizothrombin 
plus  thrombin  formation (Fig. 1, A-C) and on the amount of 
meizothrombin formed (expressed as  the percent of the  total 
amount of active product, i.e. thrombin plus meizothrombin, 
Fig. 1, D-F) in the initial phase of prothrombin activation by 
the complete prothrombinase complex (factor Xa, CaC12, fac- 
tor Va, and phospholipid). Although the overall rate of pro- 
thrombin activation was strongly dependent on the  pH, ionic 
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Meizothrombin  Formation in a 
strength,  and temperature of the reaction medium, variation 
of these parameters did not cause significant changes in  the 
relative amounts of meizothrombin and  thrombin that were 
formed. Also, variation of pH, ionic strength,  and  temperature 
hardly influenced the ratio of meizothrombin over thrombin 
formed when prothrombin was activated by prothrombinase 
complexes of different composition (data  not shown). 
It appears, therefore, that  the  data given in Table I are 
representative for a wide variety of experimental conditions 
and that the relative contributions of meizothrombin and 
thrombin to  the overall rate of prothrombin  activation  are 
not influenced by changes in pH,  temperature, or ionic 
strength of the reaction medium. 
Effect of Prothrombin Concentration-The initial  rates of 
thrombin  and of meizothrombin formation were determined 
at different prothrombin  concentrations, and  the amount of 
meizothrombin formed was expressed as percentage of the 
total  amount of active product (thrombin plus meizothrom- 
bin) generated during the initial steady state of prothrombin 
activation. The dependence of the overall rate of prothrombin 
activation  as  a function of prothrombin  concentration is given 
in Fig. 2A (Miniprint). Fig. 2B shows that when prothrombin 
was activated by the complete prothrombinase complex (fac- 
tor Xa, factor Va,  CaCI2, and phospholipid) the contribution 
of meizothrombin to product generation during  prothrombin 
activation was dependent upon the prothrombin  concentra- 
tion  and increased from 40% at 0.03 p~ prothrombin to about 
85% at 2 p~ prothrombin (Fig. 2B). However, in  the absence 
of factor Va the relative amounts of meizothrombin formed 
were independent of the prothrombin  concentration,  and 80- 
90% of the active product generated was meizothrombin ir- 
respective of the amount of prothrombin  present  in the acti- 
vation mixture (Fig. 2B) and of the large variation of the 
overall rate of prothrombin  activation (Fig. 2 A ) .  
Lipid Membrane Composition-It is well known that  the 
lipid composition of procoagulant membranes may strongly 
influence their ability to accelerate coagulation factor acti- 
S ?  I I 
E 2 o t  
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FIG. 2B. Meizothrombin formation as a function of the pro- 
thrombin concentration. The  initial  rate of prothrombin  activation 
and of meizothrombin formation was determined a t  varying pro- 
thrombin  concentrations  in  the  absence  or  presence of factor Va. The 
dependence of the  rate of prothrombin  activation  on  prothrombin 
concentration is given in A.  Meizothrombin formation ( B )  is ex- 
pressed as percentage of the  total  amount of enzymatically active 
prothrombin  activation  product  (thrombin  plus  meizothrombin) 
formed a t  each  prothrombin  concentration.  Further  details  are given 
in  the legend to Fig. 1 and under “Experimental Procedures.” The 
final  concentrations of reactants were: 50 mM Hepes, pH 7.5 a t  37 “C, 
136 mM NaC1,  2.68 mM KCl, 2 mM MgClz, 25 mM glucose, 5 mg/ml 
BSA, 2 mM CaC12, 50 PM DOPS/DOPC vesicles (10:90; mol/mol), 
prothrombin  concentrations as indicated  in  the figure and 4 nM factor 
Xa without  factor Va (A) or 3 pM factor  Xa  and 5 nM factor Va (0). 
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vation. Procoagulant membranes require the presence of  neg- 
atively charged phospholipids such as phosphatidylserine, the 
major anionic phospholipid in blood  cell membranes. In  the 
experiment presented  in Fig. 3, we have measured the influ- 
ence of variation of the amount of phosphatidylserine, present 
in procoagulant membranes, on the overall rate of prothrom- 
bin activation and on the rates of thrombin  and meizothrom- 
bin formation. The effect of the variation of the mole fraction 
of phosphatidylserine on the overall rate of prothrombin 
activation is shown in Fig. 3A (Miniprint). The different 
phosphatidylserine requirements observed for prothrombin 
activation with and without factor Va is in agreement with 
an earlier  report on bovine prothrombin activation (34). Fig. 
3B shows that  the mole fraction of phosphatidylserine present 
in phospholipid vesicles also affected the relative amounts of 
meizothrombin and  thrombin formed irrespective of whether 
factor Va was present  or not. When the phosphatidylserine 
content of the vesicles  was increased from 1 to 40  mol % the 
contribution of meizothrombin to the overall rate of pro- 
thrombin activation increased from some 55% to approxi- 
mately 85%. 
Table I1 summarizes initial  rates of thrombin  and meizo- 
thrombin formation during  prothrombin activation by factor 
Xa, factor Va, and CaC12 in the presence of various procoag- 
ulant membranes. The  data presented in  this  table indicate 
that  the relative amounts of thrombin and meizothrombin 
formed were strongly dependent upon the choice of mem- 
brane. At  2 p~ prothrombin, DOPS/DOPC (10:90, mol/mol) 
vesicles yielded some 90% meizothrombin whereas in the 
presence of lipids from natural sources such as human brain 
thromboplastin,  rabbit  brain cephalin, or platelets much  less 
meizothrombin was generated. Artificial vesicles that mimic 
the composition of the platelet membrane (a mixture of 
DOPS, DOPI, DOPC, DOPE, sphingomyelin, and cholesterol 
at a molar ratio of 10:3:37:30:20:50) also showed reduced 
meizothrombin formation. 
0 
0 10 2 0  30 4 0  5 0  
PHOSPHATIDYLSERINE (mole %) 
FIG. 3B. Effect of the membrane composition on meizo- 
thrombin formation. The initial rate of prothrombin activation 
and of meizothrombin  formation were determined  on  DOPS/DOPC 
vesicles of varying  composition  both  in  the absence and  presence of 
factor Va. The dependence of the overall rate of prothrombin  acti- 
vation on membrane composition is given in A.  Meizothrombin 
formation  is  expressed as percentage of the  total  amount of enzymat- 
ically active  prothrombin  activation  product  (thrombin  plus meizo- 
thrombin)  formed at each  phospholipid composition. Further  details 
are given in the legend to  Fig. 1 and under “Experimental Proce- 
dures.” The final  concentrations of reactants were: 50 mM Hepes, pH 
7.5 a t  37 “ c ,  136 mM NaCl, 2.68 mM KCl, 2 mM  MgC12, 25 mM 
glucose, 5 mg/ml BSA, 50 p M  DOPS/DOPC vesicles with varying 
mol % DOPS as indicated in the figure, 2 p~ prothrombin, 2 mM 
CaClZ, and 3.5 nM factor  Xa  and  no  factor Va (A) or 3.5 p~ factor 
Xa  and 5 nM factor Va (0). 
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TABLE I1 
Initial  rates of thrombin  and  meizothrombin  formation  with  various  procoagulant  membranes 
The  initial  rates of thrombin  and meizothrombin (plus meizothrombin-des-fragment 1) formation by factor  Xa, 
factor Va, and CaC12 in the presence of different procoagulant membranes were determined  as described under  the 
legend to  Table I in a total volume of 350 pl of buffer at 37 “C.  The  final  concentrations reached in  the reaction 
mixture were 10 mM Hepes, pH 7.5 at  37 “ c ,  136 mM NaC1, 2.68 mM KC1, 2 mM M&&, 25 mM glucose, 5  mg/ml 
BSA, 2 p~ prothrombin, 4 pM factor Xa, 7 nM factor Va, 2 mM CaC12, and 25 p M  phospholipid vesicles, 108/ml 
sonicated or Ca2+-ionophore-stimulated platelets, 25 p~ cephalin, or thromboplastin. The concentration of 
thromboplastin given was based on a phosphate analysis of the lipid. The  platelets were stimulated for 10 min 
with 4 p~ ionophore  before addition  to  the reaction  mixture. For  further  experimental  details see the legend to 
Table I and  under  “Experimental Procedures.” 
u (molfminfmol  Xa) 
Membrane  composition Thrombin 
formation  formation 
7% 
meizo Meizothrombin 
PS/PC (10/90) 1696 6407 79 
PS/PI/PC/PE/Sph/Chol  (molar  ratio 10:3:37:30:2050) 2768 5189 65 
Stimulated  platelets 4228 1094 21 
Platelet sonicate 3527 3315 48 
Thromboplastin 4446 1804 29 
Cephalin 4310 2474 36 
Q 
z z 
1 2 0  
1 0 0  
1 2 0  
1 0 0  
8 0  
6 0  
40  
2 0  
0 
0.0 0.5 1 .O 1.5 2.0  2.5 0 10 2 0  30 40 5 0  
TIME (min) TIME (mid 
FIG. 4. Inhibition of the amidolytic activity of thrombin, meizothrombin, and of the az-macroglob- 
din-thrombin complex  by antithrombin I11 plus heparin. Inhibition of thrombin, meizothrombin,  or the 012- 
macroglobulin-thrombin complex was determined at  37 “C in a series of 1-cm Sarstedt  cuvettes  with 950 p1 of 
buffer containing 5 nM AT 111 + 20 pg/ml heparin (panel A )  or 25 nM AT 111 + 20 pg/ml heparin (panel B ) .  The 
final amounts of reactants present in the reaction mixtures were: panel A: 0, 1 nM thrombin;, 0, 1 nM 
meizothrombin; A, 1 nM a2-macroglobulin-thrombin complex, 5 nM AT 111, 20 pg/ml heparin, 100 mM Tris,  pH 
7.9 at room temperature, 175 mM NaC1,  20 mM EDTA,  and 0.5 mg/ml ovalbumin. Panel B: as in panel A except 
that 25 nM AT 111 was present,  and  the  inhibition of thrombin was not determined. At the  time  intervals indicated, 
the remaining  amidolytic  activity was determined by addition of 50 pl of S2238 (200 p~ final  concentration)  and 
was expressed as  the percentage of the amidolytic activity measured in  the absence of AT I11 and  heparin. 
Assays for the  Detection  and  Quantitation of Amidolytically 
Active Prothrombin Activation Products in Plasma-When 
prothrombin activation is analyzed in plasma one should take 
into account that  the active enzymes that  are formed during 
coagulation of plasma are susceptible to inhibition by circu- 
lating proteinase inhibitors. The major plasma inhibitors of 
thrombin  and presumably also of meizothrombin are AT I11 
and  az-M. Inhibition of thrombin and meizothrombin by AT 
I11 results in the complete disappearance of enzymatic activ- 
ity, whereas ap-M-inhibited thrombin and meizothrombin 
retain part of their activity toward small oligopeptide sub- 
strates. Thus, when prothrombin activation in plasma is 
monitored with the chromogenic substrate S2238 part of the 
amidolytic activity measured may originate from a2-M-inhib- 
ited prothrombin activation products. The experiment shown 
in Fig. 4 illustrates that assay conditions can be found in 
which the chromogenic substrate S2238 can  discriminate be- 
tween the various amidolytically active products that are 
generated during prothrombin activation in plasma. Fig. 4A 
shows the inhibition of thrombin, meizothrombin, and  the a2- 
“thrombin complex by 5 nM AT I11 in the presence of 20 
pg/ml heparin. Under these conditions thrombin was com- 
pletely inhibited within 1 min whereas there was a minor 
effect on the amidolytic activities of meizothrombin and  the 
az-M-thrombin complex. When the amount of AT I11 present 
was raised to 25 nM all free enzyme (thrombin and meizo- 
thrombin) was inhibited within 20 min whereas the thrombin- 
a*-M complex was not  inhibited (Fig. 4B). These assays were 
not affected by plasma provided that  the amount of plasma 
present was less than 0.3% (v/v). The addition of more plasma 
caused some underestimation of meizothrombin and as a 
consequence an overestimation of thrombin. Since the 
amounts of plasma required to follow prothrombin activation 
with S2238 were  very low, it was possible to monitor product 
generation during the activation of prothrombin in plasma 
with a combination of three amidolytic assays, i.e. 1) deter- 
mination of the total amidolytic activity which measures 
thrombin, meizothrombin, and  the  aZ-M complexes, 2) deter- 
mination of the amidolytic activity after incubating a plasma 
sample for 1 min with 5 nM AT I11 plus 20 pg/ml heparin 
which measures meizothrombin plus the  a2-M complexes, and 
3) determination of the amidolytic activity after incubating a 
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FIG. 5. Visualization of amidolyt- A 
ically active prothrombin activation 
products after SDS-gel electropho- 
resis. Amounts  of  meizothrombin, mei- 
zothrombin-des-fragment 1, and  throm- 
bin indicated in the figure  were  subjected 
to gel  electrophoresis  on 10% slabgels " 
(5% stacking gel) according to Laemmli 
(21) in the presence of SDS with and 
without 2 pl of plasma present in each 
sample. The amidolytically active prod- 
ucts were visualized  after electrophoresis 
and transblotting to nitrocellulose as de- 
scribed  earlier (8). Panel A,  samples run 
in the absence  of  plasma. Panel B,  sam- 
ples with 2 pl of  plasma present on each 1.0 .5 -3 -2 -1 .05 .025 
gel  ane.  Further  experimental details 
are given under "Experimental Proce- 
dures." pmoles  enzyme/lane 
plasma sample for 30 min with 25 nM AT I11 plus 20 pg/ml 
heparin which  only measures the an-M-inhibited prothrombin 
activation products. 
In a recent paper (8), we have shown that amidolytically 
active prothrombin activation products can be  visualized after 
gel electrophoresis in the presence of SDS  and  transblotting 
to nitrocellulose. This technique could also be used to identify 
prothrombin activation products in plasma. Fig.  5A shows the 
gel electrophoretic analysis of samples containing various 
amounts of an equimolar mixture of meizothrombin, meizo- 
thrombin-des-fragment 1, and  thrombin which indicated that 
rather low concentrations of enzymatically active prothrom- 
bin activation products can be detected by the amidoblot 
procedure. When the same amounts of prothrombin activa- 
tion products were electrophoresed in the presence of 2 pl of 
plasma (Fig. 5B)  the sensitivity for thrombin remained ap- 
proximately the same while there was an  as yet unexplained 
increase in the sensitivity for meizothrombin and meizo- 
thrombin-des-fragment 1. Larger amounts of plasma could 
not be applied to  the gel since in that case too much smearing 
and loss of the meizothrombin-des-fragment 1 band occurred 
(data not shown). This experiment illustrates that  the detec- 
tion limits for meizothrombin, meizothrombin-des-fragment 
1, and thrombin on the amidoblot of plasma samples were 
about 50, 25, and 150 nM, respectively. 
Generation of Prothrombin Activation Products during Co- 
agulation Initiated Via the Extrinsic Pathway-Using the 
techniques described above, the activation of prothrombin 
was monitored in defibrinated normal human plasma upon 
addition of human brain thromboplastin (Fig.  6). After ap- 
proximately 15-20 s an explosive burst of amidolytic activity 
occurred which  was  followed  by a rapid decrease in activity. 
After about 3-4 min a final plateau was reached representing 
a2-M-inhibited prothrombin activation products (Fig. 6A). 
The vast majority of the burst of the amidolytic activity 
appeared to be associated with thrombin and little or no 
meizothrombin could be detected? The highest thrombin 
concentration reached was approximately 650 nM, whereas 
the highest meizothrombin values determined remained below 
25 nM and were in fact within experimental error. These 
'The conversion of S2238 in the plasma experiments is almost 
exclusively due to thrombin and/or meizothrombin. Simultaneous 
measurements with the chromogenic substrates S2302 and S2337 
indicated that the amounts of  kallikrein,  factor  XIIa, and factor Xa 
formed were insufficient to contribute to S2238 conversion. The 
plasma concentrations of factor IXa and factor XIa and their low 
activities toward S2238 exclude the possibility that  these enzymes 
contribute to the conversion  of S2238. 
B 
- T D  
1.0 .5  .3 .2 .1 .05 .025 
pmoles enzymellane 
findings were corroborated by electrophoretic analysis of pro- 
thrombin activation products present in plasma samples 
taken at  the same time intervals (Fig. 6, B and C). In  the 
amidoblot only thrombin was detectable as a transient band 
and no other amidolytically active reaction products were 
visible (Fig. 6B). Immunologic staining with a polyvalent anti- 
human  prothrombin antibody showed that all prothrombin 
disappeared during the time course of activation (Fig. 6C). A 
band with the electrophoretic mobility of fragment 1.2 could 
clearly be seen, and  the  (transient) hrombin band was faintly 
visible underneath this band. At  later time points a band with 
the electrophoretic mobility of fragment 1 became  visible as 
well as two bands with higher M, than prothrombin (presum- 
ably representing thrombin-AT I11 complexes). This experi- 
ment also indicates that  there is no significant accumulation 
of meizothrombin during the extrinsic activation of plasma. 
Generation of Prothrombin Activation Products during Co- 
agulation Initiated via the Intrinsic Pathway-Fig. 7 (Mini- 
print) shows the result of an experiment in which prothrom- 
bin activation was monitored in defibrinated normal human 
plasma in which coagulation occurred via the intrinsic path- 
way with kaolin as initiator  and with rabbit brain cephalin 
(Fig.  7A) or activated platelets as procoagulant lipid surface 
(Fig. 7B). In  the  latter case 10 pg/ml  collagen  was present to 
ensure optimal expression of platelet procoagulant activity 
(35). The appearance of amidolytic activity was later than in 
plasma activated via the extrinsic pathway and  the maximal 
thrombin  concentrations reached were  lower.  However, with 
respect to the generation of the various prothrombin activa- 
tion products the  data obtained in plasma activated via the 
intrinsic  and  extrinsic pathways were similar (cf. Figs. 6 and 
7). I t  was observed that both in intrinsic- and extrinsic- 
activated plasma thrombin was the major prothrombin  acti- 
vation product and  that little or no meizothrombin was  de- 
tectable during the activation of plasma prothrombin. 
Comparison of Product Generation during Prothrombin Ac- 
tivation in  the Model System and in Plasma-The data pre- 
sented thus far indicate that during  prothrombin activation 
in the model system using purified coagulation factors and 
phospholipid vesicles prepared from synthetic phospholipids 
considerable amounts of meizothrombin are formed  whereas 
in the plasma milieu hardly any meizothrombin is detectable. 
There  are  three major differences between the experiments in 
the model system and in plasma. 1) In  the model system we 
used phospholipid vesicles composed of DOPS and DOPC 
while the plasma experiments were performed in the presence 
of lipids from natural sources (thromboplastin, cephalin, or 
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FIG. 6. Amidolytic and gel electrophoretic analysis of prothrombin activation  during  activation of 
plasma with thromboplastin. The time course of prothrombin activation during extrinsic coagulation was 
monitored as follows: 807 pl of defribrinated  normal human plasma was preincubated for 5 min in  a polystyrene 
tube  at 37 "C with 100 pl of buffer, and 10-pl aliquots were withdrawn for analysis a t  time 0. Reaction was started 
with the addition of 100 pl of thromboplastin and  13 pl of 1 M CaC12, and  at  the  times indicated in the figure 10- 
pl aliquots were withdrawn for quantitative  analysis of the prothrombin  activation  products (panel A )  and for gel 
electrophoretic analysis (panels B and C ) .  The final concentrations of reactants reached were: 0.8 volume 
defibrinated plasma, 200 p M  thromboplastin (by phosphate  analysis), 20 mM Hepes, pH 7.5 at  37 "C, and  13 mM 
added CaC12. Panel A ,  the 10-pl aliquot was diluted 100-fold in ice-cold buffer (100 mM Tris, 175 mM NaC1,20 mM 
EDTA, 0.5 mg/ml ovalbumin) and  the amidolytic activities (in arbitrary  units) of thrombin (0, meizothrombin 
plus meizothrombin-des-fragment 1 (O), and a2-macroglobulin-inhibited prothrombin  activation products (A) were 
determined as described under  "Experimental Procedures." The highest value of thrombin reached equalled 0.63 
phi. Panel B, the 10-pl aliquots were diluted 5-fold in SDS-electrophoresis buffer of which 20-pl samples were 
subjected to gel electrophoresis according to Laemmli (21) in the presence of SDS on  10% slabgels (5% stack). 
After electrophoresis the proteins were transblotted to nitrocellulose and  the amidolytically active prothrombin 
activation products were visualized with S2238 as described earlier (8). Panel C, after the development and 
photography of the amidoblot the nitrocellulose sheet was washed and stained immunologically with a polyclonal 
rabbit anti-human prothrombin as first  antibody and horseradish peroxidase-conjugated mouse anti-human IgG 
as second antibody. Further experimental  details are given under  "Experimental Procedures." 
platelets) which tend  to give rise to less meizothrombin (Table 
11). 2) Low concentrations of the factor Xa-factor Va complex 
were  used in the model system whereas in plasma much higher 
amounts of this complex are generated. This might cause an 
increased rate of conversion of meizothrombin into thrombin. 
And finally, 3) the experiments performed in the model system 
were carried out in the absence of inhibitors while plasma 
contains AT I11 and  a2-M which might inhibit  the thrombin 
and meizothrombin generated during prothrombin activation. 
We tested whether these differences could explain why mei- 
zothrombin does not accumulate in the plasma milieu. 
The fact that meizothrombin did not accumulate in plasma 
(Figs. 6 and 7) was not simply due to  the use of procoagulant 
lipids form natural sources (Table 11). This is concluded  from 
the fact that prothrombin activation during intrinsic coagu- 
lation in the presence of DOPS/DOPC vesicles (20/80; 
mol/mol)  also  did not result in the accumulation of detectable 
amounts of meizothrombin (data  not shown). 
The effect of high concentrations of prothrombinase on the 
time courses of product generation is shown in Fig. 8A (Min- 
iprint).  This experiment was performed in the model system 
at a concentration of factor Xa-factor Va complex  which  gave 
an initial  rate of prothrombin activation approximately equal 
to the  rate calculated from the  burst of thrombin generation 
observed in the plasma experiment presented in Fig. 6. It can 
be seen that  at such a high factor Xa  and Va concentration 
in  the model system meizothrombin was a  transient  inter- 
mediate that was rapidly formed and subsequently further 
converted into thrombin. However, it is also clear that in the 
initial phase ( t  < 30s) of prothrombin activation meizothrom- 
bin was formed in excess of thrombin and  that for a  rather 
long time period substantial  amounts of meizothrombin were 
detectable. When the same experiment was carried out  in  the 
presence of 1.6 PM AT I11 and 2.5 PM an-M there was a 
considerable effect on the time courses of generation of throm- 
bin and meizothrombin (Fig. 8B). For both products a  short 
burst of formation was  observed  which  was  rapidly  followed 
by product disappearance due to inhibition by the inhibitors 
present  and in the case of meizothrombin presumably also by 
further processing into thrombin (cf. Fig. 8A).  However, these 
experiments show that in the model system considerable 
amounts of meizothrombin still accumulated even  when pro- 
thrombin was activated at  high concentrations of factors Xa 
and Va and in the presence of the plasma protease inhibitors 
az-M  and AT 111. 
DISCUSSION 
The experiments presented in this paper were  designed to 
gain insight in the  potential significance of meizothrombin as 
a  transient intermediate during the activation of human pro- 
thrombin. In  the  first  part of this paper, we have  described 
the effect of the experimental conditions on the initial rates 
of meizothrombin and thrombin formation in a reaction sys- 
tem containing purified human coagulation factors. Our data 
indicate that under almost all experimental conditions mei- 
zothrombin is the major enzymatically active reaction product 
formed in the initial phase of prothrombin activation. Thus, 
when prothrombin is activated by factor Xa alone or by factor 
Xa (+ factor Va)  in the presence of negatively charged phos- 
pholipid vesicles consisting of a mixture of DOPS and DOPC 
(20/80, mol/mol), meizothrombin accounts for 80-90% of the 
enzymatically active product generated under initial steady 
state  rate conditions. The relative amounts of meizothrombin 
and  thrombin that are formed are not influenced by variation 
of the pH, temperature, and ionic strength of the reaction 
medium nor are they affected by changes in the concentra- 
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tions of the accessory components, phospholipid, Ca2+ ions, 
and factor Va. Activation of prothrombin by factor Xa in the 
presence of Ca2+ and factor Va appears to be an exception, 
since under these conditions the  rate of meizothrombin for- 
mation is about 4-fold  lower than  the  rate of thrombin  for- 
mation. The  data obtained with prothrombinase complexes 
of different composition confirm earlier observations with 
bovine proteins (6). The accumulation of large amounts of 
meizothrombin during prothrombin activation by the com- 
plete  prothrombinase complex in the purified system is also 
in agreement with the data of Krishnaswamy et al. (5, 7). 
Although these  authors did not  study meizothrombin forma- 
tion in the absence of factor Va our  data clearly indicate that 
also without factor Va the majority of initially formed enzy- 
matically active reaction product is in fact meizothrombin. 
This is in agreement with the recent data of Carlisle et al. 
(33) who reported the generation of significant amounts of 
meizothrombin-des-fragment 1 in the initial phase of the 
activation of bovine prethrombin 1 by factor Xa in  the absence 
of accessory components. It should be emphasized, however, 
that in the early phase of factor Xa-catalyzed prothrombin 
activation in the absence of factor Va, the non-active reaction 
intermediate  prethrombin 2 is formed in excess of both mei- 
zothrombin and  thrombin (4, 5, 33). 
Parameters that do influence the ratio of the initial  rates 
of meizothrombin and  thrombin formation are  the prothrom- 
bin  concentration  and the composition of the procoagulant 
membrane. At low concentrations of prothrombin, the major- 
ity of the enzymatically active product is  thrombin while at 
high prothrombin  concentrations more than 90% of the ini- 
tially generated product is meizothrombin. This phenomenon 
is only observed when prothrombin is activated by the com- 
plete prothrombinase complex (factor Xa, factor Va, Ca2+ 
ions,  and phospholipid). The composition of the procoagulant 
membrane also has  a  strong effect on the relative amounts of 
thrombin  and meizothrombin that  are formed. With  the syn- 
thetic negatively charged PS/PC vesicles, that  are regularly 
used in studies of prothrombin  activation (20 mol % PS/80 
mol % PC), meizothrombin appears to be formed in excess of 
thrombin. However, vesicles containing low amounts of PS 
tend  to favor thrombin production. It was further observed 
that lipid preparations from physiological sources (cephalin, 
thromboplastin, or platelet membranes) yield much lower 
relative rates of meizothrombin formation. In such lipid sus- 
pensions  thrombin is the predominant product in  all  phases 
of prothrombin  activation. This may at least be partly caused 
by the fact that these lipid preparations  contain relatively low 
amounts of PS (35-37). 
In summary, reduced meizothrombin formation is observed 
( a )  during prothrombin  activation by the factor  Xa-Va com- 
plex  in the absence of phospholipids; ( b )  when prothrombin 
is activated at low prothrombin  concentrations by the com- 
plete prothrombinase complex; and ( c )  when procoagulant 
membranes are used that contain low  mole percentages of PS. 
We  have as yet no mechanistic explanation for these phenom- 
ena. A detailed study of the effect of the different experimen- 
tal conditions on the  rate  constants of cleavage of the Arg273- 
T h F 4  and Arp322-Ile323 bonds in prothrombin may provide 
further information on this issue (cf. Ref. 33). 
Surprisingly low amounts of meizothrombin did accumulate 
during  prothrombin  activation in plasma. Almost no  meizo- 
thrombin was detectable during  a time course of prothrombin 
activation in plasma in which the coagulation cascade was 
triggered either via the extrinsic or via the intrinsic pathway. 
The reduction of meizothrombin formation in plasma may  be 
partially caused by the fact that lipid suspensions of physio- 
logical source (thromboplastin, cephalin, or platelets)  tend to 
generate less meizothrombin. This can, however, not be the 
only explanation since the use of sonicated phospholipid 
vesicles  composed of 20 mol % DOPS  and 80 mol % DOPC 
in the plasma experiments did not result in a substantial 
accumulation of meizothrombin either. 
Other obvious explanations exist for the fact that accumu- 
lation of meizothrombin in plasma will  be far less than might 
intuitively be anticipated from extrapolation of the  data ob- 
tained under steady state rate conditions in the purified 
system. It can be calculated from the burst of thrombin 
formation in plasma that under these conditions prothrombin 
is activated at a  concentration of factor Xa-Va complexes of 
approximately 1 nM, which is much higher than  the low factor 
Xa  concentrations employed in the experiments in the model 
system (approximately 4 PM factor Xa). At such high enzyme 
concentrations meizothrombin can be readily converted into 
thrombin. Another reaction that might contribute to a de- 
crease of meizothrombin accumulation is autocatalytic con- 
version of meizothrombin which results in thrombin lacking 
residues 1-13 of the A-chain (38). Autocatalysis may not be 
negligible at  the high concentrations of thrombin (some 500 
nM) generated in the plasma experiments. Finally, the pres- 
ence of the plasma protease inhibitors AT I11 and aZ-M will 
also cause a reduction of the amount of meizothrombin formed 
in plasma milieu. Data  obtained in the model system indicate 
that these  inhibitors  not only inhibit  thrombin  but may also 
be responsible for a rapid disappearance of meizothrombin. 
We feel, however, that these  explanations do not fully account 
for the complete lack of meizothrombin accumulation in the 
plasma milieu as is illustrated by the experiment presented 
in Fig. 8. In this experiment, which was performed with 
purified proteins at high factor Xa  and Va concentrations  and 
in the presence of the plasma protease inhibitors AT I11 and 
a2-M,  considerable amounts of meizothrombin were  formed. 
It seems, therefore, that a discrepancy exists between the 
plasma milieu and  the model system concerning the accumu- 
lation of meizothrombin. Such a discrepancy can be caused 
by the fact that plasma prothrombin activation does not 
proceed via meizothrombin but for a unknown reason via 
prethrombin 2. It is also possible that plasma contains an as 
yet unidentified factor that either  stimulates the conversion 
of meizothrombin into  thrombin or that specifically and effi- 
ciently inhibits  any meizothrombin that might accumulate in 
plasma. It is obvious that more experimental work is needed 
to explain the difference between the plasma and  the model 
system and  to obtain information about the possibilities that 
plasma factor(s) might interfere with product generation dur- 
ing the activation of plasma prothrombin. 
The limited amounts of meizothrombin that  are formed in 
our experiments carried out in the plasma system make it 
questionable whether meizothrombin formation has  any phys- 
iological importance. In this respect it should be mentioned, 
however, that  it has been recently reported that detectable 
amounts of meizothrombin and meizothrombin-des-fragment 
1 accumulate as  transient  intermediates  during  prothrombin 
activation on endothelial cells (39). Considering the proposed 
function of meizothrombin in the anticoagulant pathway, i.e. 
the thrombomodulin-mediated activation of protein  C on the 
endothelial cell (12), the formation of meizothrombin on the 
same cell surface may be  of physiological significance. Since 
meizothrombin formation in the experiments in the endothe- 
lial cell system (39) was only assessed in a qualitative manner 
with purified proteins, it will  be necessary to carefully quan- 
titate meizothrombin formation and to study the effect of 
other plasma proteins in order to fully appreciate the impor- 
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tance of meizothrombin accumulation on the endothelial cell 
surface. 
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Fig- 1. Mcizothrombin  formation as a function of pH, ionic strength  and temperature. 
Initial rates of prothrombin activation by the complete prothiombmase complex IXa, Va, CaC1z and 
20% WPS/8090  W P C  vesicles) were determmed  at varying pH, ionic strength or temperature in 350 
pI total reaction volume as follows: factor Xa, factor Va and phospholipid vesicles were preincubated 
for 5 mm I" the presence of 2 mM CaCI2 ~n 335 pl reaction buffer after whlch the reaction was started 
by adding 15 pi prothrombin in the same buffer. Initial ra t s   o f  prothrombin activation i .e thrombin 
plus meirothrombin formation (panel A-C) and of meimthrombin formation were determined as 
described under Expenmental Procedures Meizothrombin formation (Panel D-F) is expressed as the 
percentage  of  the  total  amount of enzymatically  active  prothrombin  activation  product 
Panel A,D 50 mM of a mixture of Mes, Heper and Tris to obtain the desired  pH at 37 'C, 136 mM NaCi, 
(meirothrombin plus thrombin) formed. The final reaction conditions were: 
2.68 mM KCI, 2 mM MgCIz. 25 mM glucose, 5  mg/ml BSA, 2 mM CaCIz, 4 pM Xa, 5 nM Va, 100 pM 
WFSIDOPC vesicles (20180; molelmole) and 2 pM prothrombin. 
Panel B,E: 50 mM Hepes (pH 7.5 at 37 "C),  NaCl as indicated in the figure and further concentrations of 
reactants .?I under A,D 
Panel C,F 50 mM Hepes IpH 7.5) and further concentrations of reactants PI under A.D. For each 
temperature the pH of the reaction buffer was adjusted to pH 7.5. 
- 0.3 
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. 0.1 
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0.0 
The initial rate of prothrombin activation i.e. thrombin plus meirothrombin formation and of 
Fi- ZA. Initial rates of pmlhmmbin activation as a function of prothrombin concentration. 
mehthrombin formation were determined  at  varying  prothrombin  concentrations in the absence or 
presence of factor Va as described under Experimental Procedures. Initial rates of prothrombin 
activation are given here (Fig. 2A) whereas meizcthrornbin formation, expressed as percentage of the 
total  amount of enzymatically  active  prothrombin  activation  product  ( hrombin  plus 
meirothrombin) formed at each prothrombin Concentration is given in Fig. 28 in the results section. 
concentrationr of reactants were: 50 mM Hepes  (pH 7.5 at 37 "C), 136 mM NaCI, 2.68 mM KCI, 2 mM 
Further details are given in the legend to Fig. 1 and in the Experimental Procedures. The final 
MgC12, 25 mM glucose, 5 mglml BSA, 2 mM CaC12. 50 pM DOPSIDOPC vesicles ( Z O l S O ;  molelmole), 
prothrombin concentrations IS indicated in the figure  and I nM factor Xa without factor Va (&A) or 
3 pM factor X L  and 5 nM factor Va (e - e). 
7000  1 .o 
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Figure 3 k  Effect of the membrane  mmposition on prothrombin  activation 
The initial rate of prothrombin actwation and of meizothrombin formation were determined on 
DOPS/DOK vesicles of varying composition both in the absence and presence of factor Va. The 
dependence of the initial r u e  of prothrombin activation on membrane composition is given here 
(Fig. 3A)  whereas  meirothrombin  formation,  expressed as percentage  of  the  total  amount  of 
enzymatically active prothrombin activation product  (thrombin  plus  meimthrombin) formed at each 
phospholipid composition is given in Fig. 38 of the resultr section. Further details are given in the 
legend to Fig. 1 and in the Experimental Procedures. The final concentrations of reactants were: 
50 mM Hepes IpH 7.5 at 37 "C). 136 mM NaCI, 2.68 mM KCI, 2 mM MgCIz,  25 mM glucose, 5 m g l d  
BSA, 50 PM DOPSIDOPC vesicles with varying mole% W P S  as indicated in the figure, 2 pM 
prothrombin,  2 mM CaC12 and 3.5 nM factor Xa and no f a m r  Va la-a) or 3.5 pM factor Xa and  5 nM 
factor va (* - *) 
0.1 o'p 81 
TIME (mbl 
Flgure 7. Time C O U ~ B I  of prothrombin activation during activation of plasma with kaolin in the 
presence of cephalin IA) and in the presence of collagen stimulated  platelets 181. 
A. 400 fl Defibrinated normal human plasma was preincubated at 37 'C with 50 pl buffer for 5 mi" 
after which 50 pl of a LaolinIrephalinlCaCI~ mixture was added  to Start activation. Final 
concentrations reached were: 0.8 volume platelet poor plasma, 25 pM cephalin (bared on phosphate 
analysis), 1 mg/ml kaolin, 20 mM Hepes (pH 7.5 at  37 "C) and 13 mM added CaCiz. At the time p i n t s  
indicated IO pl aliquots were withdrawn  and  arrayed for prothrombin activation products as described 
in the Experimental Procedures. Symbols represent the, amidolytic activity (arbitrary units) of: 
-e, thrombin; 0 - 0 ,  meimthrombin plus meimthrombin-der-fragment 1; A-A , o2-marrogiobulin 
inhibited products. The highest value of thrombin reached equalled 0.41 pM. 
8. To 350 pl defibrinated normal human plasma 100 pl washed human platelets (IxlO~/mi) were 
added  and  the mixture was incubated at 37 OC. After 5 min aaivation war started with the addition Of 
54 pl of a kaolin/mllagen mixture. The reaction was carried out  under  stirring  conditions to ensure 
optimal expression of platelet procoagulant activity (35). Final concentrations reached were: 0.7 
volume platelet p"r plasma. 2xI08/ml platelets, IO pglml collagen, 1 mglml kaolin, 20 mM Hepes 
and arsayed for prothrombin activation products as described in the Experimental Procedures. 
(pH 7.5 at 37 OC) and 13 mM added CaC12. At the time p i n t s  indicated IO pl aliquots were withdrawn 
Symbols represent the amidolytic activity (in arbitrary units) of " 0 ,  thrombin; 0-0, meizothrombin 
plus mebothrombin-des-fr~gm~"t 1; A-A, opnacroglobulin inhibited products. The highest value of 
thrombin reached equalled 0.17 pM. 
TME trnhl TWE imlnl 
P i  8. Time course of prothrombin activation in the  absence  and In the  presence of antithrombin 
1U and armamglobulin. 
Prothrombin (1.5 pM) was activated in P total volume of 300 111 containing 10 mM Hepes, 136 mM 
NaCI, 2.68 mM KCI, 2 mM MgClz, 25 mM glucose. 5 mg/mi BSA, 0.5 nM factor Xa, 5 nM factor Va, 
2 mM CaC12 and 100 pM W F W W P C  vesicles (20/80:mole/mole) in the absence (Panel A) snd in the 
presence of 1.6 pM antithrombin Ill and 2.5 pM -2-macroglobulin (Panel 8). At the time poins 
indicated aliquoa  were  withdrawn from the reaction mixture  and assayed for prothrombin activation 
products ar described in the legend to Fig. 6 a d  under Experimental Procedures. Symbols represent 
the amidolytic activity (in arbitrary units) o f  - e, thrombin; 0-0 , meimthrombin plus meiro- 
thrombin-dfsfragment 1; A-A, o2-macroglobulin-inhibited products. The highest values of thrombin 
and meirothrombin reached were 1.47 pM and 0.8 pM (Panel A) and 0.73 and 0.3 pM (Panel 8). 
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